导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -13.02% | 4004/4773 |
| 近一周 | -2.68% | 4141/5465 |
| 近一月 | -2.93% | 2017/5421 |
| 近一季 | -2.63% | 1455/5231 |
| 近半年 | -4.71% | 2912/4920 |
| 近一年 | -16.49% | 3831/4394 |
| 近两年 | 30.61% | 2252/2954 |
| 近三年 | 10.17% | 1749/2253 |
| 成立以来 | 6.26% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-15.16% 4697/4961 |
9.20% 2495/5312 |
- - |
- - |
| 2025 | 3.68% 3104/4813 |
-7.12% 3425/3635 |
4.46% 753/4076 |
11.44% 3163/4524 |
-4.11% 3396/4813 |
| 2024 | 29.22% 134/3463 |
-5.00% 1821/2808 |
-8.57% 2248/3014 |
43.20% 15/3129 |
3.89% 757/3463 |
| 2023 | 3.93% 253/2656 |
4.16% 1036/2280 |
-2.92% 713/2385 |
7.63% 32/2515 |
-4.51% 1065/2655 |
| 2022 | -26.09% 1365/2207 |
-18.66% 1370/1919 |
2.02% 1380/2016 |
-16.19% 1418/2113 |
6.27% 373/2208 |
| 2021 | -3.65% 921/1822 |
-15.15% 1188/1255 |
7.05% 706/1330 |
4.32% 364/1466 |
1.67% 839/1822 |
| 2020 | 17.90% 754/1250 |
-11.18% 821/1028 |
9.61% 786/1067 |
19.48% 70/1164 |
1.35% 1035/1184 |
| 2019 | 45.05% 159/1092 |
48.43% 10/754 |
-7.12% 545/804 |
-5.10% 786/850 |
10.86% 93/918 |
| 2018 | -24.40% 324/834 |
- - |
- - |
- - |
-1.56% 16/691 |
| 2017 | -6.82% 517/714 |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华宝券商ETF VS. 长安沪深300非周期A(740101) |